WO2009011112A1 - Stable fat emulsion containing prostaglandin e1 - Google Patents

Stable fat emulsion containing prostaglandin e1 Download PDF

Info

Publication number
WO2009011112A1
WO2009011112A1 PCT/JP2008/001865 JP2008001865W WO2009011112A1 WO 2009011112 A1 WO2009011112 A1 WO 2009011112A1 JP 2008001865 W JP2008001865 W JP 2008001865W WO 2009011112 A1 WO2009011112 A1 WO 2009011112A1
Authority
WO
WIPO (PCT)
Prior art keywords
fat emulsion
emulsion containing
prostaglandin
containing prostaglandin
stable fat
Prior art date
Application number
PCT/JP2008/001865
Other languages
French (fr)
Japanese (ja)
Inventor
Takayuki Fukuyama
Kazuhiko Ozaki
Kenichi Hirai
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation, Taisho Pharmaceutical Co., Ltd. filed Critical Mitsubishi Tanabe Pharma Corporation
Priority to JP2009523535A priority Critical patent/JP5890599B2/en
Priority to CN200880024114A priority patent/CN101743010A/en
Priority to KR1020157002118A priority patent/KR101588558B1/en
Publication of WO2009011112A1 publication Critical patent/WO2009011112A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed is a fat emulsion containing a compound having prostaglandin E1 activity, which fat emulsion is hermetically sealed in a glass container and then heat sterilized. The residual amount of prostaglandin E1 activity after 16-month storage at 5˚C is not less than 65% but not more than 100% of the prostaglandin E1 activity at the beginning of storage.
PCT/JP2008/001865 2007-07-13 2008-07-11 Stable fat emulsion containing prostaglandin e1 WO2009011112A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009523535A JP5890599B2 (en) 2007-07-13 2008-07-11 Stable fat emulsion containing prostaglandin E1
CN200880024114A CN101743010A (en) 2007-07-13 2008-07-11 Stable fat emulsion containing prostaglandin e1
KR1020157002118A KR101588558B1 (en) 2007-07-13 2008-07-11 Stable fat emulsion containing prostaglandin E1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007184358 2007-07-13
JP2007-184358 2007-07-13

Publications (1)

Publication Number Publication Date
WO2009011112A1 true WO2009011112A1 (en) 2009-01-22

Family

ID=40259458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001865 WO2009011112A1 (en) 2007-07-13 2008-07-11 Stable fat emulsion containing prostaglandin e1

Country Status (6)

Country Link
JP (2) JP5890599B2 (en)
KR (2) KR20100053541A (en)
CN (1) CN101743010A (en)
MY (1) MY158088A (en)
TW (1) TW200920379A (en)
WO (1) WO2009011112A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013006811A (en) * 2011-06-27 2013-01-10 Fujifilm Corp Formulation packed in container
WO2019230964A1 (en) * 2018-05-31 2019-12-05 富士フイルム株式会社 Packed oil-in-water type emulsion composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102038639B (en) * 2010-12-24 2012-05-02 海南碧凯药业有限公司 Alprostadil injection preparation
CN102198095A (en) * 2011-05-03 2011-09-28 北京中海康医药科技发展有限公司 Epoprostenol fat emulsion and preparation method thereof
CN107519132A (en) * 2017-08-29 2017-12-29 辅必成（上海）医药科技有限公司 A kind of nanometer fat emulsion of Alprostadil

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02175630A (en) * 1988-12-27 1990-07-06 Matsumoto Seiyaku Kogyo Kk Method for preventing dissolution of alkali, etc., by treating inner surface of medical glass ware with metal oxide
JPH06263481A (en) * 1992-11-18 1994-09-20 Koa Glass Kk Glass product having elution preventing function for alkali and production thereof
JPH0769897A (en) * 1993-09-01 1995-03-14 Green Cross Corp:The Agent for depressing blood triglyeride level
JPH09235230A (en) * 1995-12-29 1997-09-09 Hisamitsu Pharmaceut Co Inc Iontophoresis preparation
WO1999009992A1 (en) * 1997-08-27 1999-03-04 Yoshitomi Pharmaceutical Industries, Ltd. Neovascularization promoters
JP2006188474A (en) * 2005-01-07 2006-07-20 Nichi-Iko Pharmaceutical Co Ltd Excellently stable fat emulsion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206472A (en) * 1994-01-12 1995-08-08 Nippon Electric Glass Co Ltd Borosilicate glass for medicine
JPH08104620A (en) * 1994-10-05 1996-04-23 Green Cross Corp:The Fat emulsion containing medicine
JPH08175998A (en) * 1994-12-19 1996-07-09 Takada Seiyaku Kk Lyophilized preparation using silica-coated container
JP2001328612A (en) * 2000-05-22 2001-11-27 Daiwa Tokushu Glass Kk Low alkaline glass container and its manufacturing method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02175630A (en) * 1988-12-27 1990-07-06 Matsumoto Seiyaku Kogyo Kk Method for preventing dissolution of alkali, etc., by treating inner surface of medical glass ware with metal oxide
JPH06263481A (en) * 1992-11-18 1994-09-20 Koa Glass Kk Glass product having elution preventing function for alkali and production thereof
JPH0769897A (en) * 1993-09-01 1995-03-14 Green Cross Corp:The Agent for depressing blood triglyeride level
JPH09235230A (en) * 1995-12-29 1997-09-09 Hisamitsu Pharmaceut Co Inc Iontophoresis preparation
WO1999009992A1 (en) * 1997-08-27 1999-03-04 Yoshitomi Pharmaceutical Industries, Ltd. Neovascularization promoters
JP2006188474A (en) * 2005-01-07 2006-07-20 Nichi-Iko Pharmaceutical Co Ltd Excellently stable fat emulsion

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TEAGARDEN D.L. ET AL.: "Dehydration Kinetics of Prostaglandin E1 in a lipid Emulsion", PHARMACEUTICAL RESEARCH, vol. 6, no. 3, 1989, pages 210 - 215, XP000942335 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013006811A (en) * 2011-06-27 2013-01-10 Fujifilm Corp Formulation packed in container
WO2019230964A1 (en) * 2018-05-31 2019-12-05 富士フイルム株式会社 Packed oil-in-water type emulsion composition

Also Published As

Publication number Publication date
JPWO2009011112A1 (en) 2010-09-16
TW200920379A (en) 2009-05-16
JP5890599B2 (en) 2016-03-22
JP5965944B2 (en) 2016-08-10
KR101588558B1 (en) 2016-01-28
MY158088A (en) 2016-08-30
KR20150017775A (en) 2015-02-17
JP2014224131A (en) 2014-12-04
CN101743010A (en) 2010-06-16
KR20100053541A (en) 2010-05-20

Similar Documents

Publication Publication Date Title
PH12015502542A1 (en) Stabilized pemetrexed formulation
WO2009091717A3 (en) Smokeless tobacco
WO2009011112A1 (en) Stable fat emulsion containing prostaglandin e1
WO2011159839A3 (en) Thioacetate compounds, compositions and methods of use
WO2007144770A8 (en) Bacterium
GB0514463D0 (en) Use of pinolenic acid
WO2006078659A3 (en) Stable prostaglandin-containing compositions
WO2010120368A3 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
WO2011159840A3 (en) Phenylthioacetate compounds, compositions and methods of use
GB201021827D0 (en) Flavour stick
WO2012172215A3 (en) Medical assembly comprising a medical article and a package containing said article
WO2009020067A1 (en) Liquid cosmetic preparation
EA200801859A1 (en) NONWATER COMPOSITION OF STABLE VITAMIN "C", METHOD FOR ITS PREPARATION AND APPLICATION
WO2005102248A3 (en) Silicone vesicles containing actives
WO2008136393A1 (en) Crystal of lactam compound, and method for production thereof
NZ606366A (en) Stabilization of fsh
WO2008025819A3 (en) Formulations of acetylsalicylic acid or its derivatives in soft capsules, exhibiting high stability
PE20151426A1 (en) SOLUTION TO PRESERVE VASCULAR DUCTS
WO2009060952A1 (en) Novel preparation
WO2018005844A8 (en) Fragrance compositions and methods of use thereof
WO2010025859A3 (en) Stabilization of cells by ionic liquids
WO2006056695A8 (en) Bengamides with a substituted caprolactame cycle, method for the preparation thereof, compositions containing them and use thereof
MX2009007265A (en) Salts, aqueous liquid compositions containing salts of s-(+)-abscisic acid and methods of their preparation.
WO2008099835A1 (en) Band seal for hard capsules having peg encapsulated therein
CL2013000291A1 (en) Method for packaging fungal spores comprising reducing the initial aqueous activity of the spores to less than 0.3, placing the spores inside a water vapor impermeable container and keeping the spores in the packaging for at least two days at temperatures between 15 and 25 degrees celcius.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880024114.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08776824

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12010500027

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2009523535

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107002368

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 763/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PI 20095677

Country of ref document: MY

122 Ep: pct application non-entry in european phase

Ref document number: 08776824

Country of ref document: EP

Kind code of ref document: A1